Peace and Collaborative Development Network

Global 6G Conference 2023 Opens in Nanjing, China

Retrieved on: 
Tuesday, March 28, 2023
Ministry of Science and Technology (China), Telecommunications, Communication, Senior, Speech, White paper, Global Initiative, Future Forum, Chinese Academy of Sciences, Intelligence, Research, Multimedia, Future, Multilateralism, Chinese Academy of Engineering, ITU, Ministry, Development, IEEE, ICT, Committee, Peace and Collaborative Development Network, Korea, South Korea, Dresden University, Vongo (video on demand service), Artificial intelligence, United Kingdom, Ecology, NTT, Integration, NTT Docomo, Conference, Radio, Institute of Electrical and Electronics Engineers, RNAi Global Initiative, Management, Science, Engineering, Qualcomm

NANJING, China, March 28, 2023 /PRNewswire/ -- Reported by Science and Technology Daily

Key Points: 
  • For the first time, Global 6G Conference 2023 invited important international 6G academic organizations such as Finnish 6G Flagship, Japan's 5G Forum, and Singapore's Future Communications Research & Development Program to co-organize relevant forums.At the opening ceremony, FuTURE FORUM released the Global Initiative for 6G International Cooperation and Collaboration Development.
  • The forum further discussed 6G network reform and technological innovation, enhanced international 6G cooperation, promoted the formation of global unified 6G standards and ecology, and injected new vitality and impetus to 6G technology and future industry development.
  • As Fu Jun, Deputy Secretary-General of FuTURE FORUM, said, in this important development window period of global 6G, we need to adhere to the pursuit of a unified global 6G innovation system.
  • The Global 6G Conference is a platform jointly built by top scientists and research institutions from all over the world.

Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration

Retrieved on: 
Wednesday, January 18, 2023
Health, Infectious Diseases, COVID-19, Research, Science, Pharmaceutical, Biotechnology, Emricasan, Peace and Collaborative Development Network, Immunity, CDCA, Safety, Videophilia (and Other Viral Syndromes), Organization, Immune system, Patient, HIV disease progression rates, Caspase, Commercialization, Pharmaceutical industry, COVID19

Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.

Key Points: 
  • Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.
  • Caspase molecules help build immunity to pathogens, but can also have detrimental effects on the immune system.
  • The scientists at Amerimmune had the idea that a stronger and prolonged caspase activity can cause the poor outcomes seen in some patients with COVID-19.
  • Histogen Inc. filed for arbitration to terminate the Collaborative Development and Commercialization Agreement (CDCA) between Amerimmune and Histogen Inc.

Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 12, 2022
Interim, B cell, Inflammation, NSF, Peace and Collaborative Development Network, Company, Commercialization, Private Securities Litigation Reform Act, Research, U.S. Securities and Exchange Commission, Extracellular matrix, Patient, Infection, File, NASDAQ, Review, Clinical trial, COVID-19, Trial of the century, SAN, IND, Industry, Intention, Time, Compliance, Safety, Technology, Mortgage bank, MRSA, Regeneration, Knee, Therapy, CCM, Cartilage, Security (finance), Letter, Methicillin, GLOBE, Pharmaceutical industry, Online gambling, Cryptocurrency, Allergan

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on its clinical pipeline and other corporate developments.

Key Points: 
  • We continue to anticipate top line results in the first half of 2023, assuming we complete enrollment in the fourth quarter of 2022.
  • We have initiated IND enabling activities for HST-004 and anticipate filing IND for HST-004 in the second half of 2023.
  • First Quarter Ended March 31, 2022 Financial Highlights
    For the three months ended March31, 2022 and 2021, we recognized product revenues of $0 and $0.3 million, respectively.
  • For the three months ended March31, 2022 and 2021, we recognized license revenue of $3.8 million and $12 thousand, respectively.

Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 10, 2022
Commercialization, NASDAQ, Safety, B cell, Clinical trial, Mortgage bank, Trial of the century, Private Securities Litigation Reform Act, Patient, Compliance, Company, Interim, IND, Mergers and acquisitions, U.S. Securities and Exchange Commission, MRSA, Therapy, Inflammation, Research, Extracellular matrix, Methicillin-resistant Staphylococcus aureus, Peace and Collaborative Development Network, Methicillin, CCM, Cough, Infection, Coronavirus, Quarter, Fatigue, Technology transfer, Intention, GLOBE, Collaboration, NSF, Sale, Security (finance), Knee, Potential future exposure, United States Department of Defense, Technology, COVID-19, Regeneration, Cartilage, Program, Insurance, Review, File, SAN, Headache, Pharmaceutical industry, Animal, Allergan

We now anticipate top line results in the first half of 2023, assuming we complete enrollment in the fourth quarter of 2022.

Key Points: 
  • We now anticipate top line results in the first half of 2023, assuming we complete enrollment in the fourth quarter of 2022.
  • In the second half of 2021, we initiated toxicology studies and other IND enabling activities for HST-004.
  • Emricasan COVID-19 In June 2021, we, jointly with Amerimmune LLC (Amerimmune), announced positive results from the Phase 1 study of emricasan in mild symptomatic COVID-19 patients.
  • Fourth Quarter Ended December 31, 2021 and 2020
    Product and Service Revenues for the three months ended December 31, 2021 and 2020 were $0 and $0.5million, respectively.